Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC
Status:
Completed
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
AIO-YMO/TRK-0415 (FORCE) is a Phase 2, open-label of nivolumab, patients with metastatic
non-squamous NSCLC with the necessity of radiotherapy of a metastatic site (e.g. bone) in
2nd-line or 3rd-line treatment for study group A and patients with metastatic non-squamous
NSCLC without the necessity of radiotherapy in 2nd-line or 3rd-line treatment for study Group
B.